Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00509600 · OUTCOME

Patient Response

Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia · Source last updated 2012-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
12 weeks

What was measured

Response is defined as a WBC \< 15,000 and platelets \> 75,000 at 12 weeks; toxicity is defined as a grade 3 or worse infection or non-hematologic toxicity within the first 4 weeks.

Analysis population: No analysis as only registrant inevaluable, and trial terminated early due to poor enrollment.

Groups in this outcome

Etanercept

0.8 mg/kg subcutaneously weekly for 90 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Etanercept0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Response is defined as a WBC \< 15,000 and platelets \> 75,000 at 12 weeks; toxicity is defined as a grade 3 or worse infection or non-hematologic toxicity within the first 4 weeks.
groups
  1. description
    0.8 mg/kg subcutaneously weekly for 90 days
    id
    OG000
    title
    Etanercept
population Description
No analysis as only registrant inevaluable, and trial terminated early due to poor enrollment.
reporting Status
POSTED
time Frame
12 weeks
title
Patient Response
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice